Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509439 | 1.00 | FFAR1 (0.52) | FFAR1S1PR1S1PR5S1PR3USP30 | |
| SCHEMBL14301510 | 0.82 | FFAR1 (0.55) | FFAR1S1PR1S1PR5S1PR3FFAR4 | |
| SCHEMBL6998999 | 0.82 | FFAR1 (0.55) | FFAR1S1PR1S1PR5S1PR3FFAR4 | |
| SCHEMBL6999004 | 0.82 | FFAR1 (0.55) | FFAR1S1PR1S1PR5S1PR3FFAR4 | |
| SCHEMBL13326647 | 0.81 | S1PR1 (0.41) | FFAR1S1PR1S1PR5S1PR3USP30 | |
| SCHEMBL25005998 | 0.80 | TSHR (0.41) | S1PR1S1PR5S1PR3USP30AR | |
| SCHEMBL7003669 | 0.78 | FFAR1 (0.51) | FFAR1IDO1 | |
| SCHEMBL8152908 | 0.78 | FFAR1 (0.51) | FFAR1IDO1 | |
| SCHEMBL8152906 | 0.78 | FFAR1 (0.51) | FFAR1IDO1 | |
| SCHEMBL7003675 | 0.78 | FFAR1 (0.51) | FFAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370438-A1 | IMIDAZO [1,2A]PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | Exelixis, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | FFAR1 33/4885S1PR1 1/4885S1PR5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.